Conventional preclinical models have fallen short in accurately replicating the human lung environment and immune responses to IAV infection. Animal models frequently fail to emulate the intricate host-pathogen interactions and drug delivery dynamics characteristic of human lungs, limiting their translational relevance. Moreover, rapidly advancing gene editing technologies such as CRISPR offer promising antiviral avenues; yet, their human sequence specificity complicates meaningful testing in non-human systems. This gap underscores the urgency for sophisticated experimental platforms that recapitulate the human respiratory microenvironment for rigorous evaluation of antiviral modalities.

Addressing these limitations, researchers at Harvard University’s Wyss Institute for Biologically Inspired Engineering have pioneered a microfluidic “breathing” human lung alveolus chip (Lung Chip) designed to simulate its physiological counterpart with unprecedented fidelity. Leveraging advanced organ-on-chip technology, this Lung Chip encompasses living human lung epithelial and vascular endothelial cells cultured along microfluidic channels under dynamic mechanical stretch mirroring breathing motions. This biomimetic environment fosters authentic airway barrier functions, cellular responses to infection, and inflammatory signaling, providing a versatile testbed for studying respiratory virus pathogenesis and treatment responses.

Harnessing this innovative platform, the Wyss team developed a pan-influenza CRISPR RNA-based therapeutic targeting a highly conserved sequence within the IAV genome. This approach circumvents the virus’s mutational plasticity by focusing on viral genomic regions resistant to genetic variation across diverse IAV strains, thereby offering broad-spectrum antiviral potential. The CRISPR machinery was encapsulated within engineered nanoparticles designed for efficient pulmonary delivery and selective affinity to lung epithelial cells lining the microfluidic channels of the Lung Chip. This nanoformulation ensures targeted intracellular delivery of the CRISPR RNA complexes while minimizing systemic exposure.

Upon administering a single dose of these CRISPR-loaded nanoparticles to the infected Lung Chip model, researchers observed a substantial reduction in viral load—exceeding 50%—demonstrating potent suppression of IAV replication. Beyond viral clearance, this treatment significantly attenuated the host’s inflammatory response, a major driver of disease pathology, as evidenced by dampened pro-inflammatory cytokine expression profiles. These findings attest to both the antiviral efficacy and therapeutic safety of the CRISPR RNA intervention within a human-relevant respiratory framework.

Comprehensive transcriptomic analyses further illuminated the specificity of the CRISPR RNA therapy, revealing only minimal off-target gene editing effects in the Lung Chip system. This highlights the precision of the designed CRISPR components and underscores the capability of the Lung Chip model to detect subtle transcriptomic perturbations, an essential aspect of preclinical safety assessment rarely achievable in animal models. Such high-content molecular profiling adds a critical dimension to antiviral drug development, facilitating early identification of potential adverse effects.

The convergence of microfluidic organ-on-chip technology with cutting-edge CRISPR therapeutics exemplifies a transformative paradigm for respiratory infectious disease research. By faithfully emulating human lung microenvironment dynamics and facilitating precise antiviral delivery, this platform surmounts longstanding barriers posed by species-specific differences and physiological complexity observed in traditional models. This advancement not only expedites preclinical evaluation but also strengthens translational prospects for novel interventions targeting genetically diverse and rapidly evolving pathogens like IAV.

Donald E. Ingber, M.D., Ph.D., Founding Director of the Wyss Institute, emphasizes the strategic value of the Lung Chip system in pandemic preparedness efforts. He notes that the ability to test pan-influenza CRISPR therapies for broad strain coverage and low off-target risks within human-derived tissue improves confidence in clinical applicability. Given the continual emergence of new IAV variants and the persistent threat of global outbreaks, such innovative antiviral strategies are poised to shift the trajectory in influenza management and patient outcomes dramatically.

Further supporting this work are the collaborative contributions from research groups specializing in drug delivery and molecular engineering, including Associate Director Natalie Artzi, Ph.D., whose expertise in nanoparticle science enabled efficient CRISPR RNA encapsulation and targeted pulmonary administration. Together, these interdisciplinary efforts underpin a comprehensive approach to confronting viral diseases at the intersection of bioengineering, molecular genetics, and translational medicine.

This pioneering study appears in the latest edition of the journal Lab on a Chip and represents a landmark achievement in the application of human organ-on-chip technology for infectious disease therapeutics. The integration of sophisticated microfluidics with precision gene editing lays a foundation for future explorations into other respiratory pathogens and potential combinatorial treatments, heralding a new era of personalized and adaptable antiviral medicine.

Funding support from the Defense Advanced Research Projects Agency (DARPA) and the Wyss Institute further illustrates the high priority placed on innovative preclinical models and gene editing solutions to counteract viral pandemics. The goal remains to bridge the gap between bench-side discoveries and bedside implementation, enabling rapid responses to emerging infectious threats while ensuring safety and efficacy through human-centric platforms.

In sum, the Wyss Institute’s Lung Chip serves as a cutting-edge testing ground where the next generation of CRISPR RNA therapeutics can be refined, improving our arsenal against influenza A virus and potentially other respiratory viral diseases. By faithfully recapitulating human respiratory physiology and immune responses, this system promises to accelerate antiviral development, offering hope for robust pandemic preparedness and improved global health outcomes.

Subject of Research: Cells

Article Title: Preclinical assessment of pan-influenza A virus CRISPR RNA therapeutics in a human lung alveolus chip

Web References: http://dx.doi.org/10.1039/D5LC00156K

Image Credits: Wyss Institute at Harvard University

Keywords: Influenza, Infectious diseases, In vitro assays, Disease prevention, Antivirals, Human genetics, Gene expression, Inflammatory response, Inflammation, Drug delivery, Nanoparticles, Side effects, Epidemiology, Health care, Disease outbreaks

Spinal cord injuries present complex biological challenges and often result in debilitating consequences for patients. Historically, research efforts have been hindered by a lack of standardized models, leading to variability in the results. This variability complicates the translation of findings from animal studies to human applications. Steger and his colleagues have recognized this critical gap and taken a decisive step forward by engineering an impactful solution. Their electromagnetic impactor is poised to create a more consistent and repeatable model that may accelerate progress in the understanding of spinal cord injuries and the design of potential treatments.

The electromagnetic impactor operates on a principle of precision that ensures uniform delivery of mechanical force to the spinal column. This controlled mechanism allows for exact measurements of the degree of injury inflicted upon the model organism, which in this case, is the pig. By employing this innovative tool, researchers can simulate injury scenarios that closely mimic human conditions. This enhanced reproducibility is essential for validating preclinical results that could eventually lead to novel therapeutic strategies aimed at spinal cord repair and recovery.

One of the key advantages of the new electromagnetic impactor is its versatility. It allows researchers to manipulate various parameters such as velocity, force, and angle of impact. These factors are crucial in studying the complex pathophysiology of spinal cord injuries. By simulating different injury profiles, the research team can obtain data that reflect a range of potential outcomes. This granularity of detail not only enriches the scientific understanding of spinal cord trauma but also lays the groundwork for targeted therapeutic approaches.

The implications of this research extend far beyond the laboratory. With a reliable porcine model at their disposal, researchers can evaluate novel pharmacological agents and investigate emerging technologies responsible for spinal cord regeneration. The potential for accelerated clinical trials is immense, as insights gleaned from these studies can guide the development of therapies aimed at restoring motor function and alleviating the burdens associated with spinal cord injuries.

In addition to enhancing research outcomes, the novel electromagnetic impactor addresses ethical considerations in animal research. The traditional methods of inducing spinal cord injuries often resulted in severe trauma to the animals, raising concerns about their welfare. The precision offered by the new impactor minimizes collateral damage, thereby adhering to humane practices. With a focus on ethical experimentation, researchers can conduct their studies responsibly, which is crucial in the context of increasing scrutiny on animal research practices.

Furthermore, the innovations presented by Steger et al. underscore the importance of interdisciplinary collaboration in advancing biomedical engineering. The development of the electromagnetic impactor involved contributions from engineers, biologists, and medical professionals, exemplifying how collective expertise can lead to solutions that tackle complex healthcare issues. This team approach not only magnifies the potential for future breakthroughs but also sets a precedent for collaborative efforts to address various challenges in medical research.

As spinal cord injury research evolves, it is essential to integrate technological advancements that promote reproducibility and precision. The electromagnetic impactor promises to shift the paradigm toward a more standardized and scientifically rigorous approach to preclinical studies. By producing consistent injury profiles and establishing a comprehensive dataset, the research holds the potential to transform therapeutic development, ultimately benefiting patients suffering from spinal cord dysfunction.

Moreover, the introduction of this device into spinal research holds promise for understanding the broader implications of trauma on the nervous system. By generating varied injury models, researchers may elucidate the complex interactions between cellular mechanisms, inflammation, and regeneration. This knowledge may pave the way for interventions that not only mitigate the damage sustained during injury but also stimulate recovery processes after spinal cord trauma.

In summary, the study by Steger and his team represents a significant milestone in spinal cord injury research. The introduction of the electromagnetic impactor not only promises to enhance the precision of preclinical models but also serves as a testament to the importance of collaboration in scientific advancement. As the field of spinal cord injury research continues to unfold, the findings from this study could inspire further innovations and therapeutic discoveries, ultimately improving the quality of life for countless individuals affected by these injuries.

As investigators look to the future, the potential applications of this new technology extend beyond spinal cord injuries. Similar methodologies may be applied in other areas of research where precise mechanical impact is necessary for studying tissue response to trauma. By refining the tools available to researchers, the work of Steger et al. paves the way for future advancements that could resonate across multiple domains in biomedical science.

The commitment to improving animal models is a cornerstone of ethical research practices, and the development of this electromagnetic impactor reflects that ethos. Researchers must continuously seek ways to enhance the validity and reliability of their studies while prioritizing the welfare of animal subjects. The journey toward solving the complexities of spinal cord injuries is ongoing, but innovations such as the one introduced by Steger and his team signal a brighter future for research in this critical area.

In conclusion, the promise held by the novel electromagnetic impactor is far-reaching. As researchers incorporate this tool into their studies, it will undoubtedly contribute to a more refined understanding of spinal cord injuries and inspire new avenues for therapeutic development. This research exemplifies the power of innovation in biomedical engineering and its potential to transform countless lives affected by spinal cord injuries.

Subject of Research: Spinal cord injury research using a novel electromagnetic impactor for porcine models.

Article Title: Precision in Spinal Cord Injury Research: A Novel Electromagnetic Impactor for a Consistent Porcine Model.

Article References:

Steger, L., Ghaith, A.K., Weber-Levine, C. et al. Precision in Spinal Cord Injury Research: A Novel Electromagnetic Impactor for a Consistent Porcine Model.
Ann Biomed Eng (2025). https://doi.org/10.1007/s10439-025-03836-6

Image Credits: AI Generated

DOI: 10.1007/s10439-025-03836-6

Keywords: Spinal Cord Injury, Electromagnetic Impactor, Preclinical Models, Biomedical Engineering, Animal Research.

CAR T cell therapy has emerged as one of the most promising immunotherapies for blood cancers like leukemia, offering patients a tailored assault on malignant cells by reprogramming their own immune systems. Despite impressive clinical successes, a significant fraction of patients relapse, and many suffer serious adverse effects. Scientists have long grappled with the difficulty of accurately predicting patient responses or refining these therapies due to the limitations of current preclinical testing models. Conventional two-dimensional cell cultures often fail to replicate the intricate biological environments where cancer and immune cells interact, while animal models are labor-intensive, costly, and sometimes poorly predictive of human outcomes.

This innovative device, the size of a standard microscope slide, takes a giant leap forward by replicating the three-dimensional architecture and immunological complexity of the human bone marrow — the primary niche where leukemia cells thrive. Crucially, it incorporates not just the physical structure but also a functioning human immune system, enabling real-time observations of CAR T cell dynamics in an authentic microenvironment. The chip’s design includes three distinct bone marrow regions: blood vessels, the surrounding marrow cavity, and the outer bone lining, all populated with patient-derived bone marrow cells that self-organize and secrete key extracellular matrix components such as collagen, fibronectin, and laminin. This self-assembly recreates the native tissue architecture and its multifaceted immune ecosystem.

The technical sophistication of this “bone marrow on a chip” permits the formation of vascularized niches that maintain realistic immune cell trafficking and interactions. This is a notable departure from traditional models that lack vascular complexity, often resulting in oversimplified or inaccurate assessments of therapeutic action. Using high-resolution imaging and advanced microscopy, the research team tracked individual CAR T cells as they navigated the microvascular networks, detected leukemia targets, and executed cytotoxic attacks. They observed with unprecedented clarity how CAR T cells slow their motility upon encountering malignant cells, facilitating direct engagement and destruction — a dynamic process previously difficult to capture in vitro or in animal models.

Beyond direct antitumor activity, the study revealed a fascinating “bystander effect,” where engineered CAR T cells stimulate non-targeted endogenous immune cells within the device. This interplay may shed light on both the therapeutic potentiation and adverse inflammatory side effects observed in patients, pointing to new avenues for modulating immune responses to maximize efficacy while minimizing toxicity. The chip also proved capable of modeling clinical scenarios including complete remission, resistance to therapy, and relapse, offering a powerful platform to study mechanisms underlying these varied outcomes.

A remarkable advantage of this platform is its scalability and time efficiency. While traditional animal models can take months to establish and require complex protocols, the leukemia-on-a-chip system can be assembled within half a day and supports experimental assays extending up to two weeks. This rapid turnaround opens the door for personalized medicine applications, where patient-specific bone marrow samples can be cultured and tested against multiple CAR T cell designs before selecting the optimal therapeutic approach.

The research team demonstrated that next-generation “fourth generation” CAR T cells, which incorporate enhanced engineering features for improved persistence and potency, outperformed earlier versions at lower dosages within the chip environment. This suggests the device’s utility in optimizing dose regimens and therapy formulations, potentially reducing toxic side effects while maintaining efficacy. Overall, this bioengineered platform represents an integrated, immunocompetent preclinical trial tool that bridges an important gap between bench research and patient care.

As regulatory agencies such as the FDA announce plans to phase out animal testing for drug safety evaluation, the timing of this breakthrough could not be more significant. By providing a physiologically relevant, animal-free model for immunotherapy testing, the leukemia-on-a-chip aligns with the drive toward humane, cost-effective, and predictive research alternatives. The device’s capacity to model dynamic, systemic immune responses within a controlled setting enables extensive mechanistic studies that can guide rational design of novel immunotherapies for leukemia and potentially other cancers.

This multidisciplinary collaboration underscores the power of combining mechanical engineering, microfluidics, cellular biology, and immunology to tackle complex challenges in cancer research. By harnessing patient-derived cells and reproducing the intricacies of the leukemia niche, researchers now have a cutting-edge tool to dissect immunotherapy resistance, identify biomarkers of response, and fine-tune treatments prior to clinical trials. The prospect that clinicians might one day leverage this technology to personalize therapy selection, improving outcomes and reducing side effects, heralds a new era in precision oncology.

The implications extend beyond leukemia alone. This platform’s modular design and ability to mimic tumor-immune interactions pave the way for similar “organ-on-a-chip” models targeting solid tumors and other hematologic malignancies. The convergence of bioengineering and immunotherapy now promises to accelerate the translation of laboratory insights into real-world cures in a timeframe and cost structure previously unimaginable.

In sum, the bioengineered leukemia-on-a-chip stands as a testament to innovation at the interface of engineering and medicine. It is poised to become a pivotal asset in the battle against cancer, not only enhancing our understanding of CAR T cell behavior in physiologically relevant contexts but also empowering clinicians and scientists to forge truly personalized treatment regimens. As this technology matures, it offers hope that the next wave of immunotherapies will be smarter, safer, and more effective, transforming lives for patients facing leukemia across the globe.

Subject of Research: Cells

Article Title: Bioengineered immunocompetent preclinical trial-on-chip tool enables screening of CAR T cell therapy for leukaemia

News Publication Date: 1-Jul-2025

Web References:

• Original article DOI: 10.1038/s41551-025-01428-2
• University of Pennsylvania Perelman School of Medicine: https://www.med.upenn.edu/
• FDA announcement on animal testing phase-out: https://www.fda.gov/news-events/press-announcements/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs

Image Credits: NYU Tandon Applied Micro-Bioengineering Laboratory/Courtesy of Weiqiang Chen

Keywords: Chimeric antigen receptor therapy, Blood cancer, Leukemia, Cancer treatments, Cancer immunotherapy, Biomedical engineering